Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollomics Inc. stock logo
APLM
Apollomics
$18.43
+51.3%
$10.15
$3.66
$35.98
$20.34M1.8557,379 shs682,200 shs
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$0.49
-3.6%
$0.57
$0.48
$3.89
$21.18M-0.68905,151 shs1.33 million shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$2.35
-4.5%
$2.24
$1.72
$8.27
$5.87M0.3113,154 shs194,213 shs
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$2.43
-4.0%
$2.44
$1.87
$4.20
$22.15M1.0436,091 shs78,702 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollomics Inc. stock logo
APLM
Apollomics
0.00%0.00%+213.22%+238.22%+36.44%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-3.60%-9.74%-9.46%-22.55%-81.11%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-4.47%+3.98%+4.44%-14.55%-42.82%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-3.95%-4.71%+10.45%-10.33%-20.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollomics Inc. stock logo
APLM
Apollomics
$18.43
+51.3%
$10.15
$3.66
$35.98
$20.34M1.8557,379 shs682,200 shs
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$0.49
-3.6%
$0.57
$0.48
$3.89
$21.18M-0.68905,151 shs1.33 million shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$2.35
-4.5%
$2.24
$1.72
$8.27
$5.87M0.3113,154 shs194,213 shs
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$2.43
-4.0%
$2.44
$1.87
$4.20
$22.15M1.0436,091 shs78,702 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollomics Inc. stock logo
APLM
Apollomics
0.00%0.00%+213.22%+238.22%+36.44%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-3.60%-9.74%-9.46%-22.55%-81.11%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-4.47%+3.98%+4.44%-14.55%-42.82%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-3.95%-4.71%+10.45%-10.33%-20.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apollomics Inc. stock logo
APLM
Apollomics
1.00
SellN/AN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
2.50
Moderate Buy$12.672,498.82% Upside
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
1.00
SellN/AN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
2.33
Hold$23.50867.08% Upside

Current Analyst Ratings Breakdown

Latest INM, LSTA, FBLG, and APLM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Apollomics Inc. stock logo
APLM
Apollomics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Apollomics Inc. stock logo
APLM
Apollomics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/12/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
9/10/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$16.00
8/21/2025
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$15.00
(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apollomics Inc. stock logo
APLM
Apollomics
$1.49M13.61N/AN/A$4.48 per share4.11
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/A$0.08 per shareN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.94M1.13N/AN/A$6.71 per share0.35
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$1M21.29N/AN/A$3.49 per share0.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apollomics Inc. stock logo
APLM
Apollomics
-$53.86MN/A0.00N/AN/AN/AN/AN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$11.16M-$0.36N/AN/AN/AN/A-710.25%-118.02%11/11/2025 (Estimated)
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$8.16M-$12.09N/AN/A-165.12%-93.19%-74.49%11/13/2025 (Estimated)
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$19.99M-$2.23N/AN/AN/AN/A-69.68%-59.44%11/11/2025 (Estimated)

Latest INM, LSTA, FBLG, and APLM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$0.65-$0.54+$0.11-$0.54N/A$0.07 million
7/31/2025Q1 2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$0.11-$0.12-$0.01-$0.12N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apollomics Inc. stock logo
APLM
Apollomics
N/AN/AN/AN/AN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apollomics Inc. stock logo
APLM
Apollomics
N/AN/AN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
0.93
0.93
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.02
6.99
6.47
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/A
5.77
5.77

Institutional Ownership

CompanyInstitutional Ownership
Apollomics Inc. stock logo
APLM
Apollomics
19.13%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
8.94%

Insider Ownership

CompanyInsider Ownership
Apollomics Inc. stock logo
APLM
Apollomics
N/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
20.00%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
1.43%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apollomics Inc. stock logo
APLM
Apollomics
451.10 millionN/ANot Optionable
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
1041.89 million33.51 millionN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
102.38 million2.35 millionNot Optionable
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
308.76 million7.92 millionNot Optionable

Recent News About These Companies

Lisata Therapeutics Partners with Catalent on ADC Technology
Lisata Therapeutics inks global product license deal with Catalent

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Apollomics stock logo

Apollomics NASDAQ:APLM

$18.43 +6.25 (+51.34%)
As of 10/8/2025

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

FibroBiologics stock logo

FibroBiologics NASDAQ:FBLG

$0.49 -0.02 (-3.60%)
Closing price 10/9/2025 04:00 PM Eastern
Extended Trading
$0.50 +0.01 (+2.17%)
As of 06:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

InMed Pharmaceuticals stock logo

InMed Pharmaceuticals NASDAQ:INM

$2.35 -0.11 (-4.47%)
Closing price 10/9/2025 04:00 PM Eastern
Extended Trading
$2.40 +0.05 (+2.13%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Lisata Therapeutics stock logo

Lisata Therapeutics NASDAQ:LSTA

$2.43 -0.10 (-3.95%)
Closing price 10/9/2025 04:00 PM Eastern
Extended Trading
$2.58 +0.16 (+6.38%)
As of 05:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.